Journal of Clinical Immunology and Allergy

Immunomodulating properties of the anti-cancer proton preparation on basis of greater celandine alkaloids NSC-631570 (Ukrain)

15 ^th International Conference on Immunology
July 05- 07 , 2018 Vienna , Austria

Wassil Nowicky

Nowicky Pharma/ Ukrainian Anti-Cancer Institute, Austria

Keynote: Insights Allergy Asthma Bronchitis

DOI: 10.21767/2471-304X-C1-001

Abstract

One of the most significant problems of cancer therapy is the damaging activity of anticancer drugs against normal body cells. All attempts to develop a therapeutic agent with a selective cytotoxic effect on tumor cells had no much success because of the high degree of biological identity between healthy and malignant cells. The celandine is being used in the medicine over more than 3500 years. The first data concerning the therapeutic effect of the juice of celandine in the patient with malignant melanoma were published in Germany in 1536. From that time drugs based on biologically active substances of celandine are widely used to treat cancer and non-cancer disease. It is well known that tumor cell is more negatively charged as compared to normal cell. We have used this feature of the tumor cell to give NSC-631570 a property to selectively interact with it, without endangering healthy cells and tissues. The drug is strongly positively charged. Due to this it has an ability to be selectively accumulated in tumor tissue and to induce tumor cell apoptosis only in tumor cells without harmful effect on normal cells. The potent selective antitumor effect of NSC-631570 was repeatedly proven by the results of clinical trials. Until now this preparation has been tested on over 100 cancer cell lines and on 12 normal cell lines and the results of the studies carried out in more than 120 universities and research centers (in particular at the National Cancer Institute (the USA)) have shown that the NSC-631570 killed only cancer cells without having damaged the normal cells what confirmed its selective effect.

Biography

Wassil Nowicky, Director of Nowicky Pharma and President of the Ukrainian Anti-Cancer Institute (Vienna, Austria). He has finished his study at the Radiotechnical Faculty of the Technical University of Lviv (Ukraine) by the end of 1955 with graduation to Diplomingeniueur in 1960 whose title was nostrificated in Austria in 1975. He is the author of over 300 scientific articles dedicated to cancer research. He is a real member of the New York Academy of Sciences, member of the European Union for applied immunology and of the American Association for scientific progress, Doctor honoris causa of the Open international university on complex medicine in Colombo, honorary member of the Austrian Society of a name od Albert Schweizer. He has received the award for merits of National guild of pharmasists of America, the award of Austrian Society of sanitary, hygiene and public health services and others.

E-mail: dr.nowicky@yahoo.de